How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents as Therapy Areas Become Crowded with Drugs with Similar Mechanisms of Action?
Abstract
Authors
R Paglia A Del Carlo J Schwartz EA Carter
R Paglia A Del Carlo J Schwartz EA Carter
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now